Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Ventilation of the Extremely Premature Infants Optimized by Dead Space Washout

NCT06334523 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-02-13
Last updated
2025-02-05

Condition(s) studied

Extremely Low Birthweight InfantContinuous Tracheal Gas InsufflationMedical DeviceLung ProtectionVentilator-Induced Lung Injury

Investigational drug(s) / intervention(s)

Ventilation with Dead Space Washout via Continuous Tracheal Gas Insufflation (CTGI)

Ventilation with Dead Space Washout via Continuous Tracheal Gas Insufflation (CTGI): The intervention involves adding a device which allows CTGI (the "CTGI-device") to washout the dead space in preterm mechanically ventilated infants. Dead space washout using the CTGI-device is an option added to standard ventilation, to reduce or even cancel anatomical dead space due to respiratory prostheses in intubated preterm infants.

Study summary

The Continuous Tracheal Gas Insufflation (CTGI) is a ventilation option of conventional mechanical ventilation that is used to reduce or even eliminate the dead space caused by respiratory prostheses. This objective is of particular interest in the smallest preterm infants, where the volume of anatomical dead space due to prostheses is little different from the tidal volume. The principle of this option is to continuously blow an additional flow of 0.2 L/minute at the tip of the endotracheal tube to purge expired CO2 trapped in the prostheses, to have a CO2-free volume of gas available for subsequent insufflation.

The goal of this clinical trial is to learn if Continuous Tracheal Gas Insufflation (CTGI) works to reduce ventilatory dependence in preterm infants after mechanical ventilation. It will also learn about the safety of CTGI. The main questions it aims to answer are:

* Does Continuous Tracheal Gas Insufflation (CTGI) reduce the number of days of non-invasive ventilation in extremely preterm infants who needed mechanical ventilation?
* Does Continuous Tracheal Gas Insufflation (CTGI) reduce the age at the weaning of any ventilatory support and/or oxygen supplementation.

Researchers will compare the clinical outcome of patients mechanically ventilated with the CTGI-device to the outcome of patients ventilated without the CTGI device, to see if the CTGI ventilation works to reduce ventilation dependence.

Participants will:

• Be mechanically ventilated using CTGI (if randomly assigned in the CTGI-group), for the entire endotracheal ventilation period during their stay in the neonatal intensive care unit.

Eligibility

Sex
ALL
Min age
—
Max age
7 Days
Healthy volunteers
No
Inclusion Criteria: * Gestational Age at birth between 23 weeks gestation + 0 days and 26 weeks gestation + 6days * Age between 0 and 7 days of life * Need for intubation and mechanical ventilation before day 8 of life * Availability of the Research-associated medical devices * Beneficiary of a social security system (in France: CMU or securité sociale) * Parental consent for their infant to participate in this trial Exclusion Criteria: * Known Severe Congenital Malformation (potential life-threatening malformation) * Known Preexisting Severe Intraventricular Haemorrhage (grade 3 or 4) and/or other brain abnormality that can alter life prognosis * Known Genetic Disorder (potential life-threatening malformation) * Preexistent mechanical ventilation for a duration of more than 12 hours * Participation in another interventional research trial before inclusion

Primary outcome measure(s)

  • Cumulative duration of all periods of non-invasive ventilation — From birth to the end of hospital stay, up to maximum 45 weeks of corrected gestational age.
    The cumulative duration of all periods of non-invasive ventilation, in days, starting from birth, and up to maximum 45 weeks corrected gestational age. Non-invasive ventilation includes all types of positive pressure support non-invasive ventilation and high flow nasal cannula ventilation (HFNC).

Trial sites (4)

FacilityCityRegionStatus
Centre Hospitalier Intercommunal de Creteil Créteil France
Centre Hospitalier Universitaire de Nantes Nantes France
Centre Hopistalier Universitaire Cochin Port Royal aphp Paris France
Centre hospitalier Robert Debré aphp Paris France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06334523 on ClinicalTrials.gov ↗ ← All trials in France